These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28976794)

  • 1. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
    Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
    J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
    Lee HW; Choe M
    Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
    Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
    Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
    Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
    Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
    Laba P; Wang J; Zhang J
    BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.
    Wu Q; Yang L; Liu H; Zhang W; Le X; Xu J
    Ann Surg Oncol; 2015 Jul; 22(7):2446-53. PubMed ID: 25391266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.
    Ficarra V; Martignoni G; Lohse C; Novara G; Pea M; Cavalleri S; Artibani W
    J Urol; 2006 Apr; 175(4):1235-9. PubMed ID: 16515968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems.
    Verine J; Colin D; Nheb M; Prapotnich D; Ploussard G; Cathelineau X; Desgrandchamps F; Mongiat-Artus P; Feugeas JP
    Am J Surg Pathol; 2018 Apr; 42(4):423-441. PubMed ID: 29356723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma.
    Xia Y; Liu L; Long Q; Bai Q; Wang J; Xu J; Guo J
    Urol Oncol; 2016 Jan; 34(1):5.e1-9. PubMed ID: 26411550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.
    Wagener N; Macher-Goeppinger S; Pritsch M; Hüsing J; Hoppe-Seyler K; Schirmacher P; Pfitzenmaier J; Haferkamp A; Hoppe-Seyler F; Hohenfellner M
    BMC Cancer; 2010 Oct; 10():524. PubMed ID: 20920340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.
    Parker WP; Cheville JC; Frank I; Zaid HB; Lohse CM; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2017 Apr; 71(4):665-673. PubMed ID: 27287995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma.
    Joseph RW; Kapur P; Serie DJ; Eckel-Passow JE; Parasramka M; Ho T; Cheville JC; Frenkel E; Rakheja D; Brugarolas J; Parker A
    Cancer; 2014 Apr; 120(7):1059-67. PubMed ID: 24382589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.
    White-Al Habeeb NM; Di Meo A; Scorilas A; Rotondo F; Masui O; Seivwright A; Gabril M; Girgis AH; Jewett MA; Yousef GM
    Clin Exp Metastasis; 2015 Aug; 32(6):531-41. PubMed ID: 26037892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.
    Singla N; Krabbe LM; Aydin AM; Panwar V; Woldu SL; Freifeld Y; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Bagrodia A; Kapur P; Margulis V
    Urol Oncol; 2018 Jul; 36(7):343.e1-343.e8. PubMed ID: 29748098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
    Hakimi AA; Ostrovnaya I; Jacobsen A; Susztak K; Coleman JA; Russo P; Winer AG; Mano R; Sankin AI; Motzer RJ; Voss MH; Offit K; Purdue M; Pomerantz M; Freedman M; Choueiri TK; Hsieh JJ; Klein RJ
    Cancer; 2016 Feb; 122(3):402-10. PubMed ID: 26505625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
    Parker AS; Kosari F; Lohse CM; Houston Thompson R; Kwon ED; Murphy L; Riehle DL; Blute ML; Leibovich BC; Vasmatzis G; Cheville JC
    Cancer; 2006 Jul; 107(1):37-45. PubMed ID: 16736510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
    Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
    J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.